Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B

World Journal of Gastroenterology

Volumn 11, Issue 8, 2005, Pages 1109-1114

  Fujiwara, Keiichi ^a   Yokosuka, Osamu ^a   Kojima, Hiroshige ^a   Kanda, Tatsuo ^a   Saisho, Hiromitsu ^a   Hirasawa, Hiroyuki ^a   Suzuki, Hiroshi ^b  

^a CHIBA UNIVERSITY   (Japan)

^b Takushinkai Tatsumi Hospital   (Japan)

Author keywords

Chronic hepatitis B; Immunosuppressive therapy; Severe exacerbation

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; DNA POLYMERASE; GLYCYRRHIZIC ACID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M; INTERFERON; LAMIVUDINE; METHYLPREDNISOLONE; PREDNISOLONE; PROTHROMBIN;

ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DEATH; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; MALE; MORTALITY; PLASMAPHERESIS; PROTHROMBIN TIME; SEX DIFFERENCE; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS REACTIVATION;

EID: 14844355835     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i8.1109     Document Type: Article

References (24)

1. Chemotherapy and hepatitis B. Lancet 1989; 2: 1136-1137
2. Nakamura Y, Motokura T, Fujita R, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer 1996; 78: 2210-2215
3. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
4. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6: 173-179
5. Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987; 7: 582-585
6. Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med 1982; 307: 1301-1304
7. Lam KC, Lai CL, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380-386
8. Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones A, Seeff LB. A short course of prednisolone in chronic type B hepatitis. Ann Intern Med 1986; 104: 12-17
9. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81: 987-991
10. Lau JYN, Bird GLA, Gimson AES, Alexander GJM, Williams R. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 1991; 337: 802
11. Katz R, Velasco M, Klinger J, Alessandri H. Corticosteroids in the treatment of acute hepatitis in coma. Gastroenterology 1962; 42: 258-265
12. Santantonio T, Mazzola M, Pastore G. Lamivudine is safe and effective in fulminant hepatitis B. J Hepatol 1999; 30: 551-553
13. Van Thiel DH, Friedlander L, Karda RJ, Molloy PJ, Hassanein T, Wahlstrom E, Furuki H. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44: 808-812
14. Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177-181
15. ter Borg F, Smorenburg S, de Man RA, Riethroek RC, Chamuleau RA, Jones EA. Recovery from life-threatening corticosteroid-unresponsive chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 2267-2270
16. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249-251
17. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210
18. Iino S, Tango T, Matsushima T, Toda G, Miyake K, Hino K, Kumada H, Yasuda K, Kuroki T, Hirayama C, Suzuki H. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 2001; 19: 31-40
19. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y, Mayumi M. Detection of hepatitis C virus RNA by a two-step polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-222
20. Kaplan PM, Greenman RL, Gerin TL, Purcell RH, Robinson WS. DNA polymerase associated with human hepatitis B antigen. J Virol 1973; 12: 995-1005
21. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925-2930
22. Gregory PB, Knauer M, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. N Engl J Med 1976; 294: 681-687
23. Schalm SW, Summerskill WHJ, Gitnick GL, Elveback LR. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis Bs antigen. Gut 1976; 17: 781-786
24. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-1631